PORT HUENEME, CA--(Marketwire - April 03, 2012) - Stellar Biotechnologies, Inc. ("Stellar")
(TSX VENTURE: KLH
) (PINKSHEETS: SBOTF
) (FRANKFURT: RBT), the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced today the launch of the Company's Stellar KLH™ ELISA Test Kits.
Stellar KLH™ ELISA Kits are designed for the rapid, quantitative measure of anti-KLH antibodies in serum or plasma samples. Stellar's product launch includes six different kits to measure either IgG or IgM antibodies in a range of preclinical models. The new assay kits are the first anti-KLH ELISA's (enzyme-linked immunosorbent assays) made with the Company's proprietary Stellar KLH™ Protein. This provides the unique benefits of quantitative measurements with wide dynamic range, low assay background and reproducible linearity.
"We saw that the quality of KLH used to make anti-KLH ELISA's can affect test results," said Frank Oakes, CEO and President of Stellar Biotechnologies. "Our goal was to apply Stellar KLH™ technology to improve the predictive value of pharmaceutical immunotoxicology testing using higher quality, standardized products -- both KLH protein and assays -- not available to researchers before."
In pharmaceutical research settings, KLH protein is often used as a test agent to determine a candidate drug's effects on the immune system. The tests are particularly relevant to new classes of immune modulating drugs in development. KLH can be used to assess both humoral and cellular immune responses. The Stellar KLH™ ELISA measures anti-KLH antibody levels following KLH immune stimulation.
Stellar KLH™ ELISA Test Kits, together with Stellar KLH™ Protein test agent, are intended to provide high level of control and consistency in immune response testing. Stellar's product line targets the increasing need among clinical researchers and pharmaceutical developers for improved assay sensitivity and analytical performance.
About Stellar KLH™ ELISA Test Kits
Download Stellar KLH™ ELISA Brochure
Stellar KLH™ Test Kits are research use only (RUO) solid-phase, enzyme-linked immunosorbent assays for detecting IgG or IgM antibodies. The kits are validated with controls and packaged complete with all components necessary for rapid, quantitative measure of anti-KLH antibodies in serum or plasma samples from murine and NHP models. The plates are pre-coated with proprietary Stellar KLH™ protein which improves performance of the assay. Stellar KLH™ protein is manufactured by Stellar Biotechnologies, Inc. using industry-leading, environmentally sound methods that ensure quality and consistent KLH. Visit www.stellarbiotech.com/products to learn more.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.